Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OPKO HealthLTS:0KCS -4.91%47 Days Sales Outstanding is 45.05 as of Jun. 2026, which is 24% below its 10-year median of 59.40. GuruFocus rates LTS:0KCS with a GF Score™ of 47/100 and a GF Value™ of $1.12 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, OPKO Health ranks better than 62.19% on this metric.
OPKO Health's average Accounts Receivable for the
three
months ended in Jun. 2026 was $80.8 Mil. OPKO Health's Revenue for the
three
months ended in Jun. 2026 was $163.6 Mil.
Hence, OPKO Health's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 45.05.
The historical rank and industry rank for OPKO Health's Days Sales Outstanding or its related term are showing as below:
LTS:0KCS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.98 Med: 59.4 Max: 72.89
Current: 55.35
During the past 13 years, OPKO Health's highest Days Sales Outstanding was 72.89. The lowest was 52.98. And the median was 59.40.
LTS:0KCS's Days Sales Outstanding is ranked better than 62.19% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs LTS:0KCS: 55.35
OPKO Health's Days Sales Outstanding
declined
from Jun. 2025 (56.89) to Jun. 2026 (45.05).
OPKO Health (LTS:0KCS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
OPKO Health Days Sales Outstanding Related Terms
OPKO Health Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for OPKO Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0KCS vs CSTL, FRNM, FLGT: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, OPKO Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OPKO Health Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where OPKO Health's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPKO Health (LTS:0KCS) has a Days Sales Outstanding of 45.05 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on OPKO Health and its competitors. This is 24% below median its historical median of 59.40. Over the past decade, OPKO Health's Days Sales Outstanding has ranged from 52.98 to 72.89. According to the industry distribution chart, OPKO Health ranks #76 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 37.8%.
Is OPKO Health's Days Sales Outstanding too high?
OPKO Health's current Days Sales Outstanding of 45.05 is 24% below median its 10-year median of 59.40. Over the past 10 years, this metric has ranged from a low of 52.98 to a high of 72.89. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. OPKO Health's value of 45.05 is 33.3% below this industry median. Based on the distribution chart, OPKO Health ranks #76 out of 201 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, OPKO Health has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's Days Sales Outstanding compare to CSTL and FRNM?
According to the Medical Diagnostics & Research industry distribution chart, OPKO Health ranks #76 out of 201 companies for Days Sales Outstanding. This puts OPKO Health in the upper half of its industry. The industry median Days Sales Outstanding is 67.59. OPKO Health's value of 45.05 is 33.3% below this benchmark. Historically, OPKO Health's own Days Sales Outstanding has ranged from 52.98 to 72.89 over the past decade. While the company's 10-year median is 59.40 vs. the industry median of 67.59, OPKO Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OPKO Health's current Days Sales Outstanding of 45.05 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on OPKO Health and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OPKO Health's current Days Sales Outstanding is 45.05, which is 24% below median its own 10-year median of 59.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (LTS:0KCS) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.12, compared to a current price of $1.55 — trading 38.4% above its estimated fair value. The current Days Sales Outstanding is 45.05, which is 24% below median its 10-year median of 59.40 and 33.3% below the Medical Diagnostics & Research industry median of 67.59. OPKO Health's overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For OPKO Health (LTS:0KCS), the current Days Sales Outstanding is 45.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OPKO Health (LTS:0KCS) Overvalued in 2026?
Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued.
The current stock price of $1.55 is trading 38.4% above its estimated GF Value™ of $1.12.
GuruFocus considers OPKO Health to be Significantly Overvalued.
Key valuation signals for LTS:0KCS:
Days Sales Outstanding: 45.05 (24% below median its 10-year median of 59.40)
GF Value™: $1.12 vs. price of $1.55 (38.4% above fair value)
Industry Position: 33.3% below the Medical Diagnostics & Research median (#76 of 201)
No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
47GF Score
Get the complete analysis for LTS:0KCS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KCS has been successfully added to your 
